Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | LTA4H | P09960 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3247655 | 1.00 | KIF11 (0.41) | KIF11KMT2ALTA4HTSHRCYP3A4 | |
| SCHEMBL19520974 | 1.00 | KIF11 (0.41) | KIF11KMT2ALTA4HTSHRCYP3A4 | |
| Hydrochloric Acid SCHEMBL25359940 | 1.00 | KIF11 (0.41) | KIF11KMT2ALTA4HTSHRCYP3A4 | |
| Hydrochloric Acid SCHEMBL25359945 | 1.00 | KIF11 (0.41) | KIF11KMT2ALTA4HTSHRCYP3A4 | |
| SCHEMBL21964104 | 0.87 | IDO1 (0.43) | KIF11IDO1 | |
| SCHEMBL25362169 | 0.87 | IDO1 (0.43) | KIF11IDO1 | |
| SCHEMBL19546158 | 0.87 | IDO1 (0.43) | KIF11IDO1 | |
| SCHEMBL31527201 | 0.86 | LTA4H (0.41) | KIF11KMT2ALTA4HTSHRCYP3A4 | |
| SCHEMBL17268486 | 0.85 | ALDH1A1 (0.42) | KMT2ALTA4HSMN1; SMN2IDO1 | |
| SCHEMBL29117253 | 0.85 | CYP3A4 (0.35) | KIF11LTA4HCYP3A4HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186392-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY HONG KONG CO LTD (HK) | 2025-06-12 | — | — | US | disclosed |
| US-12167998-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (CN) | 2024-12-17 | — | — | US | disclosed |
| EP-3514158-B1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC (US) | 2022-10-12 | — | — | EP | disclosed |
| US-20220151992-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2022-05-19 | — | — | US | disclosed |
| US-11077094-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-20200206189-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2020-07-02 | — | — | US | disclosed |
| US-10441571-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-10441572-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2019-10-15 | — | — | US | disclosed |
| EP-3514158-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | Aptinyx Inc. (US) | 2019-07-24 | — | — | EP | disclosed |
| EP-2951183-B1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC (US) | 2019-03-13 | — | — | EP | disclosed |
| US-20160289240-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2016-10-06 | — | — | US | disclosed |
| US-20160122359-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2016-05-05 | — | — | US | disclosed |
| EP-2951183-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | Aptinyx Inc. (US) | 2015-12-09 | — | — | EP | disclosed |
| WO-2014120783-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | NAUREX, INC. (US) | 2014-08-07 | — | — | WO | disclosed |
| EP-1856100-B1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2010-05-05 | — | — | EP | disclosed |
| US-7632832-B2 | CGRP receptor antagonists | MERCK & CO., INC. (US) | 2009-12-15 | — | — | US | disclosed |
| EP-1856100-A4 | CGRP RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20080125413-A1 | Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2008-05-29 | — | — | US | disclosed |
| EP-1856100-A2 | CGRP RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006078554-A2 | CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160289240-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | KIF11 2892/4885KMT2A 1466/4885LTA4H 2423/4885 |
| US-20250186392-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | KIF11 2892/4885KMT2A 1466/4885LTA4H 2423/4885 |
| US-12167998-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | KIF11 2892/4885KMT2A 1466/4885LTA4H 2423/4885 |
| US-20220151992-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | KIF11 2892/4885KMT2A 1466/4885LTA4H 2423/4885 |
| US-10441571-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | KIF11 2892/4885KMT2A 1466/4885LTA4H 2423/4885 |
| US-20200206189-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | KIF11 2892/4885KMT2A 1466/4885LTA4H 2423/4885 |
| US-10441572-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | KIF11 2892/4885KMT2A 1466/4885LTA4H 2423/4885 |
| US-20080125413-A1 | Cgrp Receptor Antagonists | CALCRL, NPY1R, CCKBR | KIF11 3787/4885KMT2A 3717/4885LTA4H 920/4885 |
| US-20160122359-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN2B | KIF11 2251/4885KMT2A 2709/4885LTA4H 2759/4885 |
| US-11077094-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | KIF11 2892/4885KMT2A 1466/4885LTA4H 2423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.